Use of anakinra in severe COVID-19: A case report
oleh: Giovanni Filocamo, Davide Mangioni, Paola Tagliabue, Stefano Aliberti, Giorgio Costantino, Francesca Minoia, Alessandra Bandera
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2020-07-01 |
Deskripsi
Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).